insulin users - could you give me any statistics that show that
insulin users have increased over time, e.g., an estimate of insulin
users today versus 5 years ago (or 1,2, 10 years ago - basically any
sort of comparison is great). Thanks.

---

Request for Question Clarification by tar_heel_v-ga on 25 Jan 2003 07:53 PST

Are you looking for those that inject insulin or take it orally or both?

-THV

---

Clarification of Question by kellyclose-ga on 25 Jan 2003 08:24 PST

Ah - actually I would like both.

Those on insulin injected (or pump)
Those taking oral drugs to fight diabetes.

Thank you!

Greetings kellyclose-

I have been unable to find the data on insulin use in the exact form
you requested. However, I have found information that strongly
indicates that insulin use increases each year.

The prevalence of insulin-dependent diabetes mellitus (IDDM) in the
United States is estimated to be about 300,000-500,000 individuals of
all ages. There may also be about 0.3% of the U.S. population who have
adult-onset IDDM (on-
set at age 30 years) and an unknown number of adults identified as
NIDDM (non-insulin-dependent diabetes mellitus) who have slowly
progressive
IDDM. 

The incidence of IDDM is about 30,000 new cases each year.

http://216.239.37.100/search?q=cache:PVfsMPjKoncC:www.niddk.nih.gov/health/diabetes/dia/chpt3.pdf+insulin+use+statistics&hl=en&lr=lang_en&ie=UTF-8


NIH statistics
 17 million people--6.2 percent of the population--have diabetes.
Diagnosed: 11.1 million people 
Undiagnosed: 5.9 million people

Among adults with diagnosed diabetes, about 11 percent take both
insulin and oral medications, 22 percent take insulin only, 49 percent
take oral medications only, and 17 percent do not take either insulin
or oral medications.
http://www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm

the U.S. insulin market has been effectively a monopoly. With an 81
percent share, Indianapolis-based Eli Lilly & Co. (NYSE:LLY) dominates
this $936 million business, according to 1998 data from IMS Health
Inc. The only other player here has been Novo Nordisk A/S (NYSE:NVO)
of Bagsværd, Denmark. Worldwide Lilly has a 50 percent share of the
$2.4 billion insulin market with 1998 sales of $1.2 billion. Novo
Nordisk follows with 42 percent on sales of about $1 billion.
But worldwide there is a third competitor in the insulin market,
Hoechst Marion Roussel AG, a wholly owned subsidiary of Hoechst AG
(NYSE:HOE), based in Frankfurt, Germany. It reported insulin sales
last year of $165 million.

May 2002 Investor Update from Novo Nordisk
http://wwwprod.novonordisk.com/old/press/perspective/2002may/4.html
North America
Sales of insulin and delivery systems in North America increased by
13%.

Global retail sales of diabetes drugs for the 12 months through
September 2000 were US$8.1 billion, a 19 percent rise over the prior
12-month period. The leading category of drugs was the oral
antidiabetics, accounting for 63% or US$5.1 billion of worldwide
retail sales. The other major drug category for diabetes treatment is
Insulin, which comprised the remainder of sales. IMS Health predicts
that the retail market for diabetes medications will exceed US$20
billion annually by 2006.
http://www.protemix.co.nz/diabetes/drugmarket.asp

The global insulin market is currently worth nearly $3 billion and is
growing at 14%
http://www.diabeticinvestor.com/mission.php

Search strategy: insulin use; insulin sales; insulin market; insulin
statistics; diabetis statistics


If you have questions about this response or require additional
information, please post a Request for Clarification before rating
this answer.

Nellie Bly
Google Answers Researcher